PIK3CA-话题@MedSci

#PIK3CA#

16篇内容 | 1120人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2237372, encodeId=8147223e372f0, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=近2万例晚期前列腺癌分析PIK3CA基因变异特征，或能筛选靶向/免疫治疗获益人群, objectType=article, longId=851454, objectId=b9a28514547e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing.jpg, objectUrl=/article/show_article.do?id=b9a28514547e, replyNumber=0, likeNumber=23, createdTime=2024-11-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b9a28514547e, moduleTitle=近2万例晚期前列腺癌分析PIK3CA基因变异特征，或能筛选靶向/免疫治疗获益人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a28514547e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2007526, encodeId=0c4b200e526d4, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=J Clin Oncol：PIK3CA激活突变肿瘤的新药物——Copanlisib！, objectType=article, longId=295439, objectId=db26295439f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db26295439f3, replyNumber=0, likeNumber=93, createdTime=2022-04-30, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db26295439f3, moduleTitle=J Clin Oncol：PIK3CA激活突变肿瘤的新药物——Copanlisib！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db26295439f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007523, encodeId=b05b200e52386, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, objectType=article, longId=205897, objectId=fcad20589ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad20589ed6, replyNumber=0, likeNumber=71, createdTime=2021-03-05, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad20589ed6, moduleTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcad20589ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007525, encodeId=ac41200e5256f, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=71, createdTime=2022-05-08, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007524, encodeId=6cdc200e52468, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好, objectType=article, longId=209307, objectId=690420930ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690420930ed9, replyNumber=0, likeNumber=104, createdTime=2021-04-19, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690420930ed9, moduleTitle=JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=690420930ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007522, encodeId=2995200e52231, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批, objectType=article, longId=198589, objectId=2f9119858915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9119858915, replyNumber=0, likeNumber=75, createdTime=2020-08-17, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9119858915, moduleTitle=也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f9119858915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007520, encodeId=f0d6200e520e1, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Clinica Chimica Acta：靶向测序检测卵巢癌透明细胞癌中ARID1A和PIK3CA的高频突变, objectType=article, longId=177306, objectId=0ffd1e730650, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffd1e730650, replyNumber=0, likeNumber=82, createdTime=2020-04-08, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffd1e730650, moduleTitle=Clinica Chimica Acta：靶向测序检测卵巢癌透明细胞癌中ARID1A和PIK3CA的高频突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ffd1e730650)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007521, encodeId=8ac7200e52167, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Science：PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强, objectType=article, longId=182671, objectId=0fe91826e1a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fe91826e1a0, replyNumber=0, likeNumber=66, createdTime=2020-09-04, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fe91826e1a0, moduleTitle=Science：PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fe91826e1a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007519, encodeId=621b200e51909, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌, objectType=article, longId=167492, objectId=4e2216e4929e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2216e4929e, replyNumber=0, likeNumber=69, createdTime=2020-04-21, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2216e4929e, moduleTitle=FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2216e4929e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007518, encodeId=81cc200e51831, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=PNAS：致癌基因PIK3CA以剂量依赖性方式促进细胞干性, objectType=article, longId=163750, objectId=f22d163e50b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f22d163e50b3, replyNumber=0, likeNumber=85, createdTime=2019-11-22, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f22d163e50b3, moduleTitle=PNAS：致癌基因PIK3CA以剂量依赖性方式促进细胞干性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f22d163e50b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007517, encodeId=bb5b200e51725, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, objectType=article, longId=156162, objectId=125715616238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125715616238, replyNumber=0, likeNumber=75, createdTime=2019-10-08, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125715616238, moduleTitle=CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125715616238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤, objectType=article, longId=137692, objectId=2bc713e69248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bc713e69248, replyNumber=0, likeNumber=79, createdTime=2018-11-28, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bc713e69248, moduleTitle=CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bc713e69248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007515, encodeId=72f7200e51576, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, objectType=article, longId=123846, objectId=166d123846a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=166d123846a2, replyNumber=0, likeNumber=67, createdTime=2018-04-19, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=166d123846a2, moduleTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=166d123846a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007514, encodeId=b114200e51409, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, objectType=article, longId=120634, objectId=1dba1206345c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dba1206345c, replyNumber=0, likeNumber=69, createdTime=2018-06-02, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dba1206345c, moduleTitle=CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dba1206345c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007513, encodeId=bbbb200e5132e, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Sci Rep：致癌性PIK3CA的转化在乳腺上皮细胞中的影响, objectType=article, longId=95542, objectId=34a495542a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34a495542a8, replyNumber=0, likeNumber=74, createdTime=2017-04-22, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34a495542a8, moduleTitle=Sci Rep：致癌性PIK3CA的转化在乳腺上皮细胞中的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34a495542a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007512, encodeId=fb03200e51224, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=肺部鳞癌常见基因改变—PIK3CA扩增和突变, objectType=article, longId=48309, objectId=227448309ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=227448309ca, replyNumber=0, likeNumber=87, createdTime=2015-11-07, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=227448309ca, moduleTitle=肺部鳞癌常见基因改变—PIK3CA扩增和突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=227448309ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007511, encodeId=274c200e51146, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, objectTitle=Nat Rev Clin Oncol：PIK3CA可作为阿司匹林辅助治疗结直肠癌的生物标志物, objectType=article, longId=14474, objectId=32b7144e415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b7144e415, replyNumber=0, likeNumber=81, createdTime=2013-12-18, rootId=0, userName=xinmeili, userId=f49517, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b7144e415, moduleTitle=Nat Rev Clin Oncol：PIK3CA可作为阿司匹林辅助治疗结直肠癌的生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b7144e415)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PIK3CA

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #PIK3CA#

近2万例晚期前列腺癌分析PIK3CA基因变异特征，或能筛选靶向/免疫治疗获益人群

2024-11-17发表于上海

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

J Clin Oncol：PIK3CA激活突变肿瘤的新药物——Copanlisib！

2022-04-30

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效

2021-03-05

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2022-05-08

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

JCO：阿贝西利联合氟维司群对PIK3CA突变HR+/HER2-晚期乳腺癌患者效果良好

2021-04-19

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

也是**一个靶向PIK3CA突变乳腺癌的药物Piqray，在欧洲获批

2020-08-17

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Clinica Chimica Acta：靶向测序检测卵巢癌透明细胞癌中ARID1A和PIK3CA的高频突变

2020-04-08

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Science：PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强

2020-09-04

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

FDA批准诺华的Piqray用于治疗PIK3CA突变的晚期或转移性乳腺癌

2020-04-21

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

PNAS：致癌基因PIK3CA以剂量依赖性方式促进细胞干性

2019-11-22

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

CLIN CANCER RES：PI3K和CDK4/6联合抑制治疗PIK3CA突变肺鳞状细胞癌

2019-10-08

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤

2018-11-28

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究

2018-04-19

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

CLIN CANCER RES：AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌

2018-06-02

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Sci Rep：致癌性PIK3CA的转化在乳腺上皮细胞中的影响

2017-04-22

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

肺部鳞癌常见基因改变—PIK3CA扩增和突变

2015-11-07

xinmeili (审核中...)

前往app查看评论内容

#PIK3CA#

Nat Rev Clin Oncol：PIK3CA可作为阿司匹林辅助治疗结直肠癌的生物标志物

2013-12-18

科室
- - 订阅+
  - 更多科室
工具
服务